Cargando…

Stem Cell-Associated Signatures Help to Predict Diagnosis and Prognosis in Ovarian Serous Cystadenocarcinoma

Ovarian serous cystadenocarcinoma (OV) is a fatal gynecologic cancer with a five-year survival rate of only 46%. Resistance to platinum-based chemotherapy is a prevalent factor in OV patients, leading to increased mortality. The platinum resistance in OV is driven by transcriptome heterogeneity and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Li, Zhang, Weiwei, Qiu, Jinxin, Zhang, Weiling, Lu, Mengmeng, Wang, Jiaqian, Jin, Yunfeng, Xi, Qinghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164874/ https://www.ncbi.nlm.nih.gov/pubmed/37168445 http://dx.doi.org/10.1155/2023/4500561

Ejemplares similares

Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma
por: Zhu, Yu-Ting, et al.
Publicado: (2023)

A novel ferroptosis related gene signature is associated with prognosis in patients with ovarian serous cystadenocarcinoma
por: Yu, Zhixiang, et al.
Publicado: (2021)

Gastric metastasis of ovarian serous cystadenocarcinoma
por: Yang, Shiqiang
Publicado: (2018)

A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma
por: Liu, Li-Wei, et al.
Publicado: (2016)

An Immune-Related Gene-Based Signature as Prognostic Tool in Ovarian Serous Cystadenocarcinoma
por: Shi, Fengjuan, et al.
Publicado: (2021)

Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis
por: Liu, Hui, et al.
Publicado: (2020)

Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma
por: Zhang, Jue, et al.
Publicado: (2018)

Comprehensive analysis of the expression of sodium/potassium-ATPase α subunits and prognosis of ovarian serous cystadenocarcinoma
por: Huang, Wei, et al.
Publicado: (2020)

Gene Expression Subtyping Reveals Immune alterations:TCGA Database for Prognosis in Ovarian Serous Cystadenocarcinoma
por: Feng, Chunxia, et al.
Publicado: (2021)

Serous cystadenocarcinoma of the spleen
por: Chou, Chung Kuao, et al.
Publicado: (2017)

TRPs in Ovarian Serous Cystadenocarcinoma: The Expression Patterns, Prognostic Roles, and Potential Therapeutic Targets
por: Zhang, Cheng, et al.
Publicado: (2022)

Genome-Wide Identification and Validation of Gene Expression Biomarkers in the Diagnosis of Ovarian Serous Cystadenocarcinoma
por: Zalfa, Francesca, et al.
Publicado: (2022)

Low expression of acyl-CoA thioesterase 13 is associated with poor prognosis in ovarian serous cystadenocarcinoma
por: Lv, Xiaofeng, et al.
Publicado: (2023)

Mining TCGA database for gene expression in ovarian serous cystadenocarcinoma microenvironment
por: Xu, Youzheng, et al.
Publicado: (2021)

A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma
por: Guo, Wenna, et al.
Publicado: (2018)

Development and Validation of an RNA-Binding Protein-Based Prognostic Model for Ovarian Serous Cystadenocarcinoma
por: He, Yunan, et al.
Publicado: (2020)

ANXA2P2: A Potential Immunological and Prognostic Signature in Ovarian Serous Cystadenocarcinoma via Pan-Carcinoma Synthesis
por: Zhang, Yanna, et al.
Publicado: (2022)

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma
por: Shi, Zhiwen, et al.
Publicado: (2021)

KRT19 is a Promising Prognostic Biomarker and Associates with Immune Infiltrates in Serous Ovarian Cystadenocarcinoma
por: Sun, Zhe, et al.
Publicado: (2023)

Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma
por: Yang, San-Duk, et al.
Publicado: (2016)

Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma
por: Cho, Sang Yeon, et al.
Publicado: (2017)

Comprehensive analysis of LDHAP5 pseudogene expression and potential pathogenesis in ovarian serous cystadenocarcinoma
por: Lin, Shitong, et al.
Publicado: (2020)

Assessment of Significant Pathway Signaling and Prognostic Value of GNG11 in Ovarian Serous Cystadenocarcinoma
por: Jiang, Ming-Min, et al.
Publicado: (2021)

Abnormal expressions of PURPL, miR-363-3p and ADAM10 predicted poor prognosis for patients with ovarian serous cystadenocarcinoma
por: Zhang, Ruitao, et al.
Publicado: (2023)

Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen
por: Cho, Wontae, et al.
Publicado: (2011)

Pancreatic Serous Cystadenocarcinoma: A Case Report and Review of the Literature
por: King, Jonathan C., et al.
Publicado: (2009)

Serous cystadenocarcinoma of the pancreas: report of a case and management reflections
por: Bramis, K, et al.
Publicado: (2012)

Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary.
por: Lee, Jong Hoon, et al.
Publicado: (2002)

Identification of bromodomain-containing proteins prognostic value and expression significance based on a genomic landscape analysis of ovarian serous cystadenocarcinoma
por: Zhang, Juan, et al.
Publicado: (2022)

Identification of a 3-mRNA signature as a novel potential prognostic biomarker in patients with ovarian serous cystadenocarcinoma in G2 and G3
por: Zhou, Jiahua, et al.
Publicado: (2019)

Serous cystadenocarcinoma of the mesentery in a man: case report and review of literature
por: Obuchi, Toru, et al.
Publicado: (2014)

LPAR1 regulates the development of intratumoral heterogeneity in ovarian serous cystadenocarcinoma by activating the PI3K/AKT signaling pathway
por: Cui, Ran, et al.
Publicado: (2019)

Age is associated with prognosis in serous ovarian carcinoma
por: Deng, Fei, et al.
Publicado: (2017)

Metastatic ovarian papillary cystadenocarcinoma to the small intestine serous surface: report of a case of high-grade histopathologic malignancy
por: Khaki, Fariba, et al.
Publicado: (2014)

Targetable IDH1 mutation identified in a rare case of pancreatic serous cystadenocarcinoma but not a series of serous cystadenomas
por: Zhang, Yuxi, et al.
Publicado: (2022)

Testicular papillary serous cystadenocarcinoma: a rare case report and review of the literature
por: Geramizadeh, Bita, et al.
Publicado: (2011)

Serous Microcystic Cystadenocarcinoma of the Pancreas with Synchronous Liver Metastases: Clinical Characteristics and Management
por: Massaras, Dimitrios, et al.
Publicado: (2020)

Long non-coding RNA FOXP4-AS1 is a prognostic biomarker and associated with immune infiltrates in ovarian serous cystadenocarcinoma
por: Liao, Cheng, et al.
Publicado: (2021)

The circular RNA expression profile in ovarian serous cystadenocarcinoma reveals a complex circRNA–miRNA regulatory network
por: Zhuang, Minhui, et al.
Publicado: (2021)

Social, Genetics and Histopathological Factors Related to Titin (TTN) Gene Mutation and Survival in Women with Ovarian Serous Cystadenocarcinoma: Bioinformatics Analysis
por: Gomes, Fabiana de Campos, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k8daqnf55kid60p3lr4d78hnfk